Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …

To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …

Background Owing to its unique location and multifaceted metabolic functions, epicardial
adipose tissue (EAT) is gradually emerging as a new metabolic target for coronary artery …

Background Exploratory analysis to determine the effect of semaglutide versus comparators
on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes. Methods …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used to treat diabetes and
obesity and reduce rates of major cardiovascular events, such as stroke and myocardial …